menu

Expert Insights: Managing Patients with CKD, Hyperkalemia, and Continued RAASi Therapy Through a Case Study Approach

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Expert Insights: Managing Patients with CKD, Hyperkalemia, and Continued RAASi Therapy Through a Case Study Approach

close
3 chapters
Play All
0.25 credits
15 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Hyperkalemia (HK) is a major impediment to optimizing RAASi therapy in various patient populations. Fortunately, newer treatments are now available to mitigate this adverse effect. In this chapterized activity, Drs. Colbert, Toto, and Weir discuss strategies to manage a patient with chronic kidney disease (CKD) and resistant hypertension. Find out who is at risk for HK and explore the use of a potassium binder as both a short- and long-term solution.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Matthew R. Weir, MD
    Division Head, Nephrology
    University of Maryland
    School of Medicine
    Baltimore, MD 

    Consulting Fees: AstraZeneca, Boehringer-Ingelheim, Janssen, Merck, Relypsa, Vifor Pharma

    Faculty:
    Gates Colbert, MD, FASN
    Assistant Clinical Professor
    Texas A&M College of Medicine
    Dallas, TX 

    Commercial Interest Speakers Bureau: Janssen, Tricida, Inc., Vifor Pharma

    Robert Toto, MD
    Associate Dean, Translational Science
    UT Southwestern Medical Center
    Dallas, TX

    Consulting Fees: Astra-Zeneca, ACI, Boehringer-Ingelheim, Bayer, Medscape, Reata, Vifor

    Reviewers/Content Planners/Authors:

    • Nancy Ashley, MSN, APRN, ANP-BC, CCRN, CEN, has nothing to disclose.
    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • The PIM planners and others have nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss strategies to overcome concerns about hyperkalemia in patients with CKD receiving RAAS inhibitor therapy
    • Explain the therapeutic rationale of using potassium binders to manage hyperkalemia in the short and long term to improve outcomes in patients with CKD who are taking RAAS inhibitors
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, primary care physicians, nurse practitioners, nurses, and all allied healthcare professionals involved in the diagnosis and treatment of HF and CKD.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ReachMD Healthcare ImageIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Continuing Nursing Education
    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

    Jointly provided by the Global Learning Collaborative and Prova Education in of Medicine in collaboration with Postgraduate Institute for Medicine

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Hyperkalemia (HK) is a major impediment to optimizing RAASi therapy in various patient populations. Fortunately, newer treatments are now available to mitigate this adverse effect. In this chapterized activity, Drs. Colbert, Toto, and Weir discuss strategies to manage a patient with chronic kidney disease (CKD) and resistant hypertension. Find out who is at risk for HK and explore the use of a potassium binder as both a short- and long-term solution.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Matthew R. Weir, MD
    Division Head, Nephrology
    University of Maryland
    School of Medicine
    Baltimore, MD 

    Consulting Fees: AstraZeneca, Boehringer-Ingelheim, Janssen, Merck, Relypsa, Vifor Pharma

    Faculty:
    Gates Colbert, MD, FASN
    Assistant Clinical Professor
    Texas A&M College of Medicine
    Dallas, TX 

    Commercial Interest Speakers Bureau: Janssen, Tricida, Inc., Vifor Pharma

    Robert Toto, MD
    Associate Dean, Translational Science
    UT Southwestern Medical Center
    Dallas, TX

    Consulting Fees: Astra-Zeneca, ACI, Boehringer-Ingelheim, Bayer, Medscape, Reata, Vifor

    Reviewers/Content Planners/Authors:

    • Nancy Ashley, MSN, APRN, ANP-BC, CCRN, CEN, has nothing to disclose.
    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • The PIM planners and others have nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss strategies to overcome concerns about hyperkalemia in patients with CKD receiving RAAS inhibitor therapy
    • Explain the therapeutic rationale of using potassium binders to manage hyperkalemia in the short and long term to improve outcomes in patients with CKD who are taking RAAS inhibitors
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, primary care physicians, nurse practitioners, nurses, and all allied healthcare professionals involved in the diagnosis and treatment of HF and CKD.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ReachMD Healthcare ImageIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Continuing Nursing Education
    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

    Jointly provided by the Global Learning Collaborative and Prova Education in of Medicine in collaboration with Postgraduate Institute for Medicine

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 Oct 2021
Webpack App